Kim Allan

Kim Allan serves as a Lecturer in the Department of Diagnostic Imaging at Glasgow Caledonian University, Glasgow, United Kingdom. Her academic role bridges clinical imaging practice and diabetes research, with particular focus on cardiovascular complications in Type 1 Diabetes patients. She contributes to advancing medical knowledge through rigorous clinical investigation within the university's health sciences framework.

Her research expertise spans Diabetes Research, Cardiovascular Medicine, and Metabolic Disorders, with specialization in clinical pharmacology and randomized controlled trials. She investigates metformin's therapeutic potential beyond glucose control, examining its cardiovascular and metabolic effects through methodologically robust study designs. This work addresses critical gaps in diabetes management where cardiovascular disease remains the leading cause of mortality.

Kim Allan's landmark 2017 REMOVAL study publication in The Lancet Diabetes and Endocrinology has generated exceptional scholarly impact with 303 citations. The research demonstrated how cardiovascular outcomes in Type 1 Diabetes can be influenced by pharmacological interventions, establishing new evidence for clinical practice. Its widespread adoption in 5 clinical guideline sources and policy documents confirms translational significance beyond academic circles.

Her research aligns with UN Sustainable Development Goal 3 (Good Health and Well-being), addressing diabetes complications through evidence-based approaches. While specific current grants aren't detailed, her leadership in the REMOVAL study indicates strong capability in securing major research funding. Prospective collaborators would find her expertise valuable for diabetes clinical trials and cardiovascular risk assessment projects within diagnostic imaging contexts.